Dual GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes

Tirzepatide, a dual GIP/GLP-1 receptor agonist, has demonstrated better dose-dependent efficacy in reducing HbA1c and body weight than placebo and other treatments.

• Tirzepatide is administered as a once-weekly subcutaneous injection for type-2 diabetes.
• In the SURPASS program, tirzepatide showed greater reductions in HbA1c and body weight at doses of 5, 10, and 15mg compared to placebo, basal insulin, and two GLP-1 analogues.
• The cardiovascular protective effect of tirzepatide is being evaluated against dulaglutide in the SURPASS-CVOT study.
• Ongoing studies are exploring tirzepatide for treating obesity and metabolic-associated fatty liver disease.
• Gastrointestinal tolerance for tirzepatide is similar to that of GLP-1 analogues, though it has a higher incidence of diarrhea.
• The future role of dual or triple receptor agonists in managing type-2 diabetes and obesity will depend on their risk/benefit ratio.

AI simplified